Sickle Cell Disease (SCD) is one of the most prevalent hematological diseases in the world. Despite the immense progress in molecular knowledge about SCD in last years few therapeutical sources are currently available. Nowadays the treatment is performed mainly with drugs such as hydroxyurea or other fetal hemoglobin inducers and chelating agents. This review summarizes current knowledge about the treatment and the advancements in drug design in order to discover more effective and safe drugs. Patient monitoring methods in SCD are also discussed. © 2011 Bentham Science Publishers Ltd.92113127Ingram, V.M., Abnormal human haemoglobins. III. The chemical difference between normal and sickle cell haemoglobins (1959) Biochim. Biophys. Acta, 36, pp. 402-411Pauling, L., Itano, H.A., Singer, S.J., Wells, I.C., Sickle cell anemia: A molecular disease (1949) Science, 110, pp. 543-548Watson, J., Stahman, A.W., Billelo, F.P., The significance of the paucity of sickle cells in neighborn negro infants (1948) Am. J. Med. Sci, 215, pp. 419-423Perutz, M.F., Rossmann, M.G., Cullis, A.F., Structure of haemo- globin: A three-dimensional Fourrier synthesis at 5-5A resolution obtained by X-ray analysis (1960) Nature, 185, pp. 416-422Richer, J., Chudley, A.E., The hemoglobinopathies and malaria (2005) Clin. Genet, 68 (4), pp. 332-336Bonds, D.R., Three decades of innovation in the management of sickle cell disease: The road to understanding the sickle cell disease clinical phenotype (2005) Blood Rev, 19, pp. 99-110Ilozue, C., Cipolotti, R., Melo, C.A., Gurgel, R.Q., Cuevas, L.E., Estimating the post-neonatal prevalence of sickle cell disease in a Brazilian population (2010) Trop. Med. Int. Health, 15 (10), pp. 1125-1131Adachi, K., Kim, J., Ballas, S., Surrey, S., Asakura, T., Facilitation of Hb S polymerization by the substitution of Glu for Gln at (3121 (1988) J. Biol. Chem, 263 (12), pp. 5607-5610Steinberg, M.H., Barton, F., Castro, O., Pegelow, C.H., Ballas, S.K., Kutlar, A., Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia. Risk and benefits up to 9 years of treatment (2003) JAMA, 289, pp. 1645-1651Zennadi, R., Chien, A., Xu, K.E., Batchvarova, M., Telen, M.J., Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium (2008) Blood, 112 (8), pp. 3474-3483Taylor, J.G., Nolan, V.G., Mendelsohn, L., Kato, G.J., Gladwin, M.T., Steinberg, M.H., Chronic hyper-hemolysis in sickle cell anemia: Association of vascular complications and mortality with less frequent vasoocclusive pain (2008) PLoS One, 3 (5), pp. 1-8Kato, G.J., McGowan, V., Machado, R.F., Little, J.A., Taylor, J., Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease (2006) Blood, 107, pp. 2279-2285El Nemer, W., Wautier, M., Rahuel, C., Gane, P., Hermand, P., Galacteros, F., Wautier, J., Kim, C.V., Endothelial Lu/BCAM glycoproteins are novel ligands for red blood cell 41 integrin: Role in adhesion of sickle red blood cells to endothelial cells (2007) Blood, 109 (8), pp. 3544-3551Wagner, M.C., Eckman, J.R., Wick, T.M., Sickle cell adhesion depends on hemodynamics and endothelial activation (2004) J. Lab. Clin. Med, 144 (5), pp. 260-267Okpala, I., Daniel, Y., Haynes, R., Odoemene, D., Goldman, J., Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells (2002) Eur. J. Haematol, 69, pp. 135-144Okpala, I., The intriguing contribution of white blood cells to sickle cell disease - a red cell disorder (2004) Blood Rev, 18, pp. 65-73Ma, Q., Wyszynski, D.F., Farrell, J.J., Kutlar, A., Farrer, L.A., Baldwin, C.T., Steinberg, M.H., Fetal haemoglobin in sickle cell anemia: Genetic determinants of response to hydroxyurea (2007) Pharma-cogenomics, 7 (6), pp. 386-394Steinberg, M.H., Pathophysiologically based drug treatment of sickle cell disease (2006) Trends Pharmacol. Scienc, 27 (4), pp. 204-210O'Connell, D., Neglected diseases (2007) Nature, 449, p. 157Chung, M.C., Ferreira, E.I., Santos, J.L., Giarolla, J., Rando, D.G., Almeida, A.E., Bosquesi, P.L., Blau, L., Prodrugs for the treatment of neglected diseases (2008) Molecules, 13 (3), pp. 616-677Yamey, G., Torreele, E., The world's most neglected diseases (2002) BMJ, 325 (7357), pp. 176-177Porter, J.B., Pathophysiology of transfusional iron overload: Contrasting patterns in thalassemia major and sickle cell disease (2009) Hemoglobin, 33 (S1), pp. 37-45Inati, A., Khoriaty, E., Musallam, K.M., Taher, A.T., Iron chelation therapy for patients with sickle cell disease and iron overload (2010) Am. J. Hematol, 85 (10), pp. 782-786Porter, J.B., Practical management of iron overload (2001) Br. J. Haematol, 115, pp. 239-252Brittenham, G.M., Griffith, P.M., Nienhuis, A.W., McLaren, C.E., Young, N.S., Tucker, E.E., Allen, C.J., Harris, J.W., Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major (1994) N. Engl. J. Med, 331, pp. 567-573Lindsey, W.T., Olin, B.R., Deferasirox for transfusion-related iron overload: A clinical review (2007) Clin. Ther, 29 (10), pp. 2154-2166Wambebe, C., Khamofu, H., Momoh, J.A., Ekpeyong, M., Audu, B.S., Njoku, O.S., Bamgboye, E.A., Ogunyale, O., Double-blind, placebo-controlled, randomised cross-over clinical trial of NIPRISAN in patients with sickle cell disorder (2001) Phytomedicine, 8 (4), pp. 252-261Iyamu, E.W., Turner, E.A., Asakura, T., Niprisan (Nix-0699) improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions (2003) Br. J. Haematol, 122 (6), pp. 1001-1008Oniyangi, O., Cohal, D.H., Phytomedicines (medicines derived from plants) for sickle cell disease (2010) Cochrane Database Syst. Rev, 10, pp. CD004448Ekeke, G.I., Shode, F.O., The reversion of sickle cells by Cajanus cajan (1985) Planta Med, 51 (6), pp. 504-507Akojie, F.O., Fung, L.W., Antisickling activity of hydroxybenzoic acid in Cajanus cajan (1992) Planta Med, 58 (4), pp. 317-320Akinsulie, A.O., Temiye, E.O., Akanmu, A.S., Lesi, F.E., Whyte, C.O., Clinical evaluation of extract of Cajanus cajan (Ciklavit) in sickle cell anaemia (2005) J. Trop. Pediatr, 51 (4), pp. 200-205Ouattara, B., Jansen, O., Angenot, L., Guissou, I.P., Frédérich, M., Fondu, P., Tits, M., Antisickling properties of divanilloylquinic acids isolated from Fagara zanthoxyloides Lam. (Rutaceae) (2009) Phytomedicine, 16 (2-3), pp. 125-129ICAGEN: Ion Channel Advances, , http://www.icagen.com/randd/sicklecell.html, accessed November 28, 2010Lew, V.L., Tiffert, T., Etzion, Z., Perdomo, D., Daw, N., Mac-Donald, L., Bookchin, R.M., Distribution of dehydration rates generated by maximal Gardos - channel activation in normal and sickle red blood cells (2005) Blood, 105 (1), pp. 361-367Joiner, C., Rettig, R.K., Jiang, M.R., Franco, P.S., Urea stimulation of KCl cotransport induces abnormal volume reduction in sickle re-ticulocytes (2007) Blood, 109, pp. 1728-1735Bennekou, P., Franceschi, L., Pedersen, O., Lian, L., Asakura, T., Evans, G., Brugnara, C., Christophersen, P., Treatment with NS3623, a novel Cl-conductance blocker, ameliorates erythrocyte dehydration in transgenic SAD mice: A possible new therapeutic approach for sickle cell disease (2001) Blood, 97 (5), pp. 1451-1457McNaughton-Smith, G.A., Burns, J.F., Stocker, J.W., Rigdon, G.C., Creech, C., Arrington, S., Shelton, T., Franceschi, L., Novel inhibitors of the gardos channel for the treatment of sickle cell disease (2008) J. Med. Chem, 51 (4), pp. 976-982Park, S., Hayes, B.L., Marankan, F., Mulhearn, D.C., Wanna, L., Mesecar, A.D., Santarsiero, B.D., Venton, D.L., Regioselective covalent modification of hemoglobin in search of antisickling agents (2003) J. Med. Chem, 46 (6), pp. 936-953Safo, M.K., Abdulmalik, O., Danso-Danquat, R., Burnett, J.C., Nokuri, S., Joshi, G.S., Musayev, F.N., Abraham, D.J., Structural basis for the potent antisickiling effects of a novel class of five membered heterocyclic aldehydic compounds (2004) J. Med. Chem, 47, pp. 4665-4676Abdulmalik, O., Safo, M.K., Chen, Q., Yang, J., Brugnara, C., Ohene-Frempong, K., Abraham, D.J., Asakura, T., 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells (2005) Br. J. Haematol, 128, pp. 552-561Koshy, M., Dorn, L., Ressler, L., Molokie, R., Lavelle, D., Tal-Ischy, N., Hoffman, R., de Simone, J., 2-deoxy 5-azacytidine and fetal haemoglobin induction in sickle cell anemia (2000) Blood, 96 (7), pp. 2379-2384Dover, G.J., Brusilow, S., Samid, D., Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate (1992) New Engl. J. Med, 327, pp. 569-570Hanft, V.N., Fruchtman, S.R., Pickens, C.V., Rosse, W.F., Howard, T.A., Ware, R.E., Acquired DNA mutations associated with in vivo hydroxyurea exposure (2000) Blood, 95 (11), pp. 3589-3593Charache, S., Terrin, M.L., Moore, R.D., Dover, G.J., Barton, F.B., Eckert, S.V., Macmahon, R.P., Bonds, D.R., The investigators of the multicenter study of hydroxyurea in sickle cell anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia (1995) N. Engl. J. Med, 332, pp. 1313-1322King, S.B., The nitric oxide producing reactions of hydroxyurea (2003) Curr. Med. Chem, 10, pp. 437-452Lou, T.F., Singh, M., Mackie, A., Li, W., Pace, B.S., Hydroxyurea generates nitric oxide in human erythroid cells: Mechanisms for gamma-globin gene activation (2009) Exp. Biol. Med, 234 (11), pp. 1374-1382Conran, N., Oresco-Santos, C., Acosta, H.C., Fattori, A., Saad, S.T., Costa, F.F., Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients (2004) Br. J. Haematol, 124, pp. 547-554Nahavandi, M., Perlin, E., Kassim, O.O., Wyche, M.O., Castro, O., Tavakkoli, F., Upregulation of TNF-a by hydroxyurea in patients with sickle cell anemia (2000) Blood, 96 (11), p. 14Najean, Y., Rain, J.D., Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years (1997) Blood, 90, pp. 3370-3377Fruchtman, S.M., Mack, K., Kaplan, M.E., Peterson, P., Berk, P.D., Wasserman, L.R., From efficacy to safety: A Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera (1997) Semin. Hematol, 34, pp. 17-23Ferm, V.H., Severe development malformations: Malformations induced by urethane and hydroxyurea in the hamster (1966) Arch. Pathol, 81, pp. 174-177Depass, L.R., Weaver, E.V., Comparison of teratogenic effects of aspirin and hydroxyurea in the Fischer 344 and Wistar strains (1982) J. Toxicol. Environ. Health, 10 (2), pp. 297-305Santos, J.L., Varanda, E.A., Lima, L.M., Chung, M.C., Mutagenicity of new lead compounds to treat sickle cell disease symptoms in a Salmonella/microssome assay (2010) Int. J. Mol. Sci, 11, pp. 779-788Aliyu, Z.Y., Tumblin, A.R., Kato, G.J., Current therapy of sickle cell disease (2005) Haematologica, 90, pp. 7-12Konturek, S.K., Konturek, P.C., Role of nitric oxid in the digestive system (1995) Digestion, 56, pp. 1-13Kaul, D.K., Zhang, X., Dasgupta, T., Fabry, M.E., Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress (2008) Am. J. Physiol. Heart Circ. Physiol, 295, pp. 39-47Morris, C.R., Kuypers, F.A., Larkin, S., Sweeters, N., Simon, J., Vichinsky, E.P., Styles, L.A., Arginine therapy: Anovel strategy to induce nitric oxide production in sickle cell disease (2000) Brit. J. Haematol, 111, pp. 498-500Gladwin, M.T., Schechter, A.N., Ognibene, F.P., Coles, W.A., Reiter, C.D., Schenke, W.H., Csako, G., Cannon, R.O., Divergent nitric oxide bioavailability in men and women with sickle cell disease (2003) Circulation, 107 (2), pp. 271-278Cokic, V.P., Smith, R.D., Beleslin-Cokic, B.B., Njoroge, J.M., Miller, J.L., Gladwin, M.T., Schechter, A.N., Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase (2003) J. Clin. Invest, 111 (2), pp. 231-239Weiner, D.L., Hibberd, P.L., Betit, P., Cooper, A.B., Botelho, C.A., Brugnara, C., Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease (2003) J. Am. Med. Assoc, 289 (9), pp. 1136-1142Mack, A.K., Kato, G.J., Sickle cell disease and nitric oxide: A paradigm shift (2006) Int. J. Biochem. Cell Biol, 38, pp. 1237-1243Orringer, E.P., Casella, J.F., Ataga, K.I., Koshy, M., Adams-Graves, P., Luchtman-Jones, L., Wun, T., Grindel, J.M., Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial (2001) JAMA, 286 (17), pp. 2099-2106Adams-Graves, P., Kedar, A., Koshy, M., Steinberg, M., Veith, R., Ward, D., Crawford, R., Emanuele, M., RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: A pilot study (1997) Blood, 90 (5), pp. 2041-2046Ballas, S.K., Files, B., Luchtman-Jones, L., Benjamin, L., Swerd-Low, P., Hilliard, L., Coates, T., Grindel, J.M., Safety of purified poloxamer 188 in sickle cell disease: Phase I study of a non-ionic surfactant in the management of acute chest syndrome (2004) Hemoglobin, 28 (2), pp. 85-102Cheung, A.T., Chan, M.S., Ramanujam, S., Rangaswami, A., Curl, K., Franklin, P., Wun, T., Effects of poloxamer 188 treatment on sickle cell vaso-occlusive crisis: Computer-assisted intravital microscopy study (2004) J. Investig. Med, 52 (6), pp. 402-406Gibbs, W.J., Hagemann, T.M., Purified poloxamer 188 for sickle cell vaso-occlusive crisis (2004) Ann. Pharmacother, 38 (2), pp. 320-324Brandow, A.M., Panepinto, J.A., Hydroxyurea use in sickle cell disease: The battle with low prescription rates, poor patient compliance and fears of toxicities (2010) Expert Rev. Hematol, 3 (3), pp. 255-260Thornburg, C.D., Calatroni, A., Telen, M., Kemper, A.R., Adherence to hydroxyurea therapy in children with sickle cell anemia (2010) J. Pediatr, 156, pp. 415-419Barbarín, O.A., Whitten, C.F., Bond, S., Conner-Warren, R., The social and cultural context of coping with sickle cell disease: III. stress, coping tasks, family functioning and children's adjustment (1999) J. Black Psychology, 25, pp. 356-377Davies, S.C., Gilmore, A., The role of hydroxyurea in the management of sickle cell disease (2003) Blood Rev, 17, pp. 99-109Roberts, I., The role of hydroxyurea in sickle cell disease (2003) Br. J. Haematol, 120, pp. 177-186Battersby, A.J., Knox-Macaulay, H.H., Carrol, E.D., Susceptibility to invasive bacterial infections in children with sickle cell disease (2010) Pediatr. Blood Cancer, 55 (3), pp. 401-406Ramakrishnan, M., Moïsi, J.C., Klugman, K.P., Iglesias, J.M., Grant, L.R., Mpoudi-Etame, M., Levine, O.S., Increased risk of invasive bacterial infections in African people with sickle-cell disease: A systematic review and meta-analysis (2010) Lancet Infect. Dis, 10 (5), pp. 329-337Gaston, M.H., Verter, J.I., Woods, G., Pegelow, C., Kelleher, J., Presbury, G., Zarkowsky, H., Falleta, J.M., Prophylaxis with Oral Penicillin in Children with Sickle Cell Anemia. A randomized trial (1986) N. Engl. J. Med, 314 (25), pp. 1593-1599Warren, M.D., Arbogast, P.G., Dudley, J.A., Kaltenbach, L., Ray, W.A., Wang, W.C., Cooper, W.O., Adherence to prophylactic antibiotic guidelines among medicaid infants with sickle cell disease (2010) Arch. Pediatr. Adolesc. Med, 164 (3), pp. 298-299Teach, S.J., Lillis, K.A., Grossi, M., Compliance with penicillin prophylaxis in patients with sickle cell disease (1998) Arch. Pediatr. Adolesc. Med, 152 (3), pp. 274-278Powell, R.W., Levine, G.L., Yang, Y., Mankad, V.N., Acute splenic sequestration crisis in sickle cell disease: Early detection and treatment (1992) J. Pediat. Surg, 27 (2), pp. 215-219Emond, A.M., Collis, R., Darvill, D., Higgs, D.R., Maude, G.H., Serjeant, G.R., Acute splenic sequestration in homozygous sickle cell disease: Natural history and management (1985) J. Pediat, 107 (2), pp. 201-206Girei, A.I., Alao, O.O., Joseph, D.E., Damulak, D.O., Orkuma, J., Banwat, E.B., Haematological profile of sickle cell anaemia in children with human parvovirus B19 infection in Jos, North Central Nigeria (2010) J. Clin. Med. Res, 2 (9), pp. 152-155Castro, O., Brambilla, D.J., Thorington, B., Reindorf, C.A., Scott, R.B., Gillete, P., Vera, J.C., Levy, P.S., The acute chest syndrome in sickle cell disease: Incidence and risk factors: The Cooperative Study of Sickle Cell Disease (1994) Blood, 84, pp. 643-649Vichinsky, E.P., Neumayr, L.D., Earles, A.N., Williamns, R., Lennette, E.T., Dean, D., Nickerson, B., Manci, E.A., Causes and outcomes of the acute chest syndrome in sickle cell disease (2000) N. Engl. J. Med, 342, pp. 1855-1865Boyd, J.H., Macklin, E.A., Strunk, R.C., Debaun, M.R., Asthma is associated with increased mortality in individuals with sickle cell anemia (2007) Haematologica, 92, pp. 1115-1121Velasquez, M.P., Mariscalco, M.M., Goldstein, S.L., Airewele, G.E., Erythrocytapheresis in children with sickle cell disease and acute chest syndrome (2009) Pedriatr. Blood Cancer, 53 (6), pp. 1060-1063Lionnet, F., Arlet, J.B., Bartolucci, P., Habibi, A., Ribeil, J.A., Stankovic, K., Guidelines for management of adult sickle cell disease (2009) Rev. Med. Interne, 30 (3), pp. 162-222Kumar, R., Qureshi, S., Mohanty, P., Rao, S.P., Miller, S.T., A short course of prednisone in the management of acute chest syndrome of sickle cell disease (2010) J. Pediatr. Hematol. Oncol, 32 (3), pp. 91-94Sobota, A., Graham, D.A., Heeney, M.M., Neufeld, E.J., Corticos-teroids for acute chest syndrome in children with sickle cell disease: Variation in use and association with length of stay and readmission (2010) Am. J. Hematol, 85 (1), pp. 24-28Sullivan, K.J., Kisson, N., Gauger, C., Nitric oxide metabolism and the acute chest syndrome of sickle cell anemia (2008) Pediatr. Crit. Care Med, 9 (2), pp. 159-168Atz, A.M., Wessel, D.L., Inhaled nitric oxide in sickle cell disease with acute chest syndrome (1997) Anesthesiology, 87, pp. 988-990Chang, W.L., Corate, L.M., Sinclair, J.M., van der Heyde, H.C., Continuous inhaled nitric oxide therapy in a case of sickle cell disease with multiorgan involvement (2008) J. Investig. Med, 56, pp. 1023-1027Solomon, L.R., Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: An educational void (2008) Blood, 111 (3), pp. 997-1003Rees, D.C., Olujohunghe, A.D., Parker, N.E., Stephens, A.D., Telfer, P., Wright, J., Guidelines for the management of the acute painful crisis in sickle cell disease (2003) Brit. J. Haematol, 120, pp. 744-752Booker, M.J., Blethyn, K.L., Wright, C.J., Greenfield, S.M., Pain management is sickle cell disease (2006) Chronic Illn, 2, pp. 39-50Wilkie, D.J., Molokie, R., Boyd-Seal, D., Suarez, M.L., Kim, Y.O., Zong, S., Wittert, H., Wang, Z.J., Patient-reported outcomes: Descriptors of nociceptive and neuropathic pain and barriers to effective pain management in adult outpatients with sickle cell disease (2010) J. Nat. Med. Assoc, 102 (1), pp. 18-27Nur, E., Kim, Y.S., Truijen, J., van Beers, E.J., Davis, S.C., Brandjes, D.P., Biemond, B.J., van Lieshout, J.J., Cerebrovascular reserve capacity is impaired in patients with sickle cell disease (2009) Blood, 114 (16), pp. 3473-3478Stockman, J.A., Nigro, M.A., Mishkin, M.M., Oski, F.A., Occlusion of large cerebral vessels in sickle cell anemia (1972) N. Engl. J. Med, 287, p. 847French, J.A., Kenny, D., Scott, J.P., Hoffmann, R.G., Wood, J.D., Hudetz, A.G., Hillery, C.A., Mechanisms of stroke in sickle cell disease: Sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition (1997) Blood, 89 (12), pp. 4591-4599Ohene-Frempong, K., Weiner, S.J., Sleeper, L.A., Miller, S.T., Embury, S., Moohr, J.W., Wethers, D.L., Gill, F.M., Cerebrovascular accidents in sickle cell disease: Rates and risk factors (1998) Blood, 91 (1), pp. 288-294Adams, R.J., Stroke prevention in sickle cell disease (2000) Curr. Opinion Hematol, 7 (2), p. 101Adams, R.J., Pavlakis, S., Roach, E.S., Sickle cell disease and stroke: Primary prevention and transcranial Doppler (2003) Annals Neurology, 54 (5), pp. 559-563Wang, W.C., The pathophysiology, prevention, and treatment of stroke in sickle cell disease (2007) Curr. Opinion Hematol, 14 (3), pp. 191-197Lefevre, N., Dufour, D., Gulbis, B., Le, P., Heijmans, C., Ferster, A., Use of hydroxyurea in prevention of stroke in children with sickle cell disease (2008) Blood, 111 (2), pp. 963-964Mirre, E., Brousse, V., Berteloot, L., Lambot-Juhan, K., Verlhac, S., Boulat, C., Dumont, M., Montalembert, M., Feasi-bilty and efficacy of chronic transfusion for stroke prevention in children with sickle cell disease (2010) Eur. J. Haematol, 84 (3), pp. 259-265Sarrai, M., Duroseau, H., D'augustine, J., Moktan, S., Bellevue, R., Bone mass density in adults with sickle cell disease (2007) Brit. J. Hae-matol, 136 (4), pp. 666-672Adewoye, A.H., Chen, T.C., Ma, Q., McMahon, L., Mathieu, J., Malabanan, A., Steinberg, M.H., Holick, M.F., Sickle cell bone disease: Response to vitamin D and calcium (2008) Am. J. Hematol, 83 (4), pp. 271-274Al-Turki, H., Influence of pregnancy on bone mass in sickle cell anemia (2009) West Afric. J. Med, 28 (3), pp. 169-172Diggs, L.W., Ching, R.E., Pathology of sickle cell anemia (1934) South Med. J, 27, pp. 839-845Roupret, M., Beley, S., Traxer, O., Kirsch-Noir, F., Jouannet, P., Jardin, A., Thiounn, N., Management of priapism in patients with sickle-cell anaemia (2005) Prog. Urol, 15 (3), pp. 392-396Rogers, Z.R., Priapism in sickle cell disease (2005) Hematol. Oncol. Clin. North Am, 19 (5), pp. 917-928Muneer, A., Minhas, S., Arya, M., Ralph, D.J., Stuttering priapism--a review of the therapeutic options (2008) Int. J. Clin. Pract, 62 (8), pp. 1265-1270Mantadakis, E., Ewalt, D.H., Cavender, J.D., Rogers, Z.R., Buchanan, G.R., Outpatient penile aspiration and epinephrine irrigation for young patients with sickle cell anemia and prolonged priap-ism (2000) Blood, 95, pp. 78-82Serjeant, G.R., Serjeant, B.E., Mohan, J.S., Clare, A., Leg ulceration in sickle cell disease: Medieval medicine in a modern world (2005) Hema-tol. Oncol. Clin. North Am, 19 (5), pp. 943-956Clare, A., Fitzhenley, M., Harris, J., Hambleton, I., Serjeant, G.R., Chronic leg ulceration in homozygous sickle cell disease: The role of venous incompetence (2002) Brit. J. Haematol, 119 (2), pp. 567-571Vamkavas, E.C., Relative risk of reducing the lifetime blood donation for men who have had sex with men versus currently tolerated transfusions risks (2011) Transfus. Med. Rev, 25 (1), pp. 47-60King, A.A., Tang, S., Ferguson, K.L., de Baun, M.R., An education program to increase teacher knowledge about sickle cell disease (2005) J. School Health, 75 (1), pp. 11-14Butler, D.J., Beltran, L.R., Functions of an adult sickle cell group: Education, task orientation, and support (1993) Health Soc. Work, 18 (1), pp. 49-56Kladny, B., Gettig, E.A., Krishnamurti, L., Systematic follow-up and case management of the abnormal newborn screen can improve acceptance of genetic counseling for sickle cell or other hemoglo-binopathy trait (2005) Genetics Med, 7 (2), pp. 139-142Johnson, F.L., Look, A.T., Gockerman, J., Ruggiero, M.R., Dalla-Pozza, L., Billings, F.T., Bone-marrow transplantation in a patient with sickle-cell anemia (1984) N. Engl. J. Med, 311 (12), pp. 780-783Gaziev, J., Lucarelli, G., Allogeneic cellular gene therapy for he-moglobinopathies (2010) Hematol. Oncol. Clin. North Am, 24 (6), pp. 1145-1163Bernaudin, F., Socie, G., Kuentz, M., Chevret, S., Duval, M., Ber-Trand, Y., Vannier, J.P., Gluckman, E., SFGM-TC. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease (2007) Blood, 110 (7), pp. 2749-2756Hsieh, M.M., Kang, E.M., Fitzhugh, C.D., Link, M.B., Bolan, C.D., Kurlander, R., Childs, R.W., Tisdale, J.F., Allogeneic hematopoietic stem-cell transplantation for sickle cell disease (2009) N. Engl. J. Med, 361 (24), pp. 2309-2317Olowoyeye, A., Okwundu, C.I., Gene therapy for sickle cell disease (2010) Cochrane Database Syst. Rev, 8, pp. CD007652Papanikolaou, E., Anagnou, N.P., Major challenges for gene therapy of thalassemia and sickle cell disease (2010) Curr. Gene Ther, 10 (5), pp. 404-412Gräslund, T., Li, X., Magnenat, L., Popkov, M., Barbas, C.F., Exploring strategies for the design of artificial transcription factors: Targeting sites proximal to known regulatory regions for the induction of gamma-globin expression and the treatment of sickle cell disease (2005) J. Biol. Chem, 280 (5), pp. 3707-3714Wilber, A., Tschulena, U., Hargrove, P.W., Kim, Y.S., Persons, D.A., Barbas, C.F., Nienhuis, A.W., A zinc-finger transcrip-tional activator designed to interact with the gamma-globin gene promoters enhances fetal hemoglobin production in primary human adult erythroblasts (2010) Blood, 115 (15), pp. 3033-3041Friedrich, M.J., Advances reshaping sickle cell therapy (2011) JAMA, 305 (3), pp. 239-240Hanna, J., Wernig, M., Markoulaki, S., Sun, C.W., Meissner, A., Cassady, J.P., Beard, C., Jaenisch, R., Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin (2007) Science, 318 (5858), pp. 1920-1923